Chymase (EC 3.4.21.39) is a chymotrypsin-like serine protease present in the secretory granules of mast cells, located mainly in the heart, blood vessels, and skin of in many mammalian species. 1 Its physiological substrate is angiotensin I, which upon cleavage by chymase yields angiotensin II in steps of the renin-angiotensin system. 2 In addition it is known to promote mast cell degranulation and plays a role in airway secretions and in atopic or allergic inflammation of the skin. 3 Therefore chymase is regarded as a potential therapeutic target for cardiovascular diseases as well as allergic/inflammatory diseases. 4 SPF-32629A (1) and B (2) were isolated from the cultured broth of Penicillium sp. SPF-32629 and have the inhibitory activities against human chymase with the IC 50 of 0.25 and 0.42 μg/mL, respectively, as selective inhibitors. 5 They have a 4-hydroxy-2-pyridone skeleton on phenylmethanol ( Figure  1 ). Mukkanti group reported first synthesis and structural determination of 1 and 2, however there were not the analogs developed for chymase inhibition so far. 6 In this work, 2-and 4-pyridone analogs of SPF-32629A were synthesized via short and efficient routes and evaluated as chymase inhibitors in order to establish SAR such as the necessity of 4-hydroxy-2-pyridone and the effects on C4' modification of phenyl group (a) with p-fluorophenyl (b), pchlorophenyl (c), p-tolyl (d) and p-methoxyphenyl (e).
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Our synthetic route for 2-pyridones is shown in Scheme 1. First, aryl(2-pyridinyl)methanols (3a-e) were synthesized by Grignard reagents addition to the starting material 6-methoxy-2-pyridinecarboxaldehyde. The treatment of 3 with TMSI afforded the 2-pyridones (4a-e), which were converted into the isovalerates (5a-e) along with bis-isovalerates (6a-e) under EDCI-mediated condition. The isovalerate (7a-3) was also prepared from 4 in a similar manner. 4-Pyridone analogs of SPF-32629A were synthesized from the known nitrile (8) 6 (Scheme 2). The ketones (9a-e) were given by Grignard reagents addition to 8, followed by acid treatment. With 9 in hands, NaBH 4 reduction and subsequent hydrogenolysis of the alcohol (10a-e) afforded the 4-pyridones (11a-e). Finally, 11 were converted into the isovalerates (12a-e). The diesters (13a-e) were easily hydrolyzed to afford the corresponding 12.
The inhibitory effect on chymase of SPF-32629A analogs at 100 μM is shown in Figure 2 . The IC 50 of selected analogs was tested as shown as Table 1 . The introduction of 2methoxypyridine (3 and 7) and 4-benzyloxypyridine (9 and 10) instead of 2-and 4-pyridone resulted in a loss of activity. 
Notes
Analogs (4 and 11) not having isovalerate moiety was not tolerated. Interestingly, 2-pyridone analogs (5b and 5d) into which the substituent such as F and CH 3 was incorporated on C4' exhibited considerable activities against human chymase. Whereas 4-pyridones 12 completely lost activity, 13b and 13d inhibit chymase slightly. As our results, 4hydroxy-2-pyridone skeleton is essential to inhibit chymase and C4'-substitution offer a chance to increase the biological activity.
In conclusion, 2-and 4-pyridone analogs of SPF-32629A were synthesized and evaluated for chymase inhibition. SAR studies revealed that 4-hydroxy-2-pyridone skeleton is critical to inhibition activity to human chymase and C4'modification is expected to improve activity. These findings provide the information on the structural features that influence the biological activities within this class of compounds and need attention for further investigation. 151.1, 142.2, 138.2, 137.8, 128.8, 126.4, 117.1, 104.2, 71 .5, 19.75. LRMS (ESI + ) m/z 216.2 (M+H + ).
General Procedures for Synthesis of 5a-e and 6a-e. To a solution of the 2-pyridone 4 (1.0 eq) in CH 2 Cl 2 was added EDCI (1.2 eq), DMAP (0.3 eq) and isovaleric acid (1.2 eq) at 0 °C. After stirring at ambient temperature for 1 h, the reaction mixture was washed with saturated aq. NaHCO 3 and extracted with EtOAc. A combined organic layer was washed with brine, dried over MgSO 4 and concentrated in vacuo. The residue was purified by column chromatography (CH 2 Cl 2 /MeOH) to afford the monoester 5 and diester 6. General Procedures for Synthesis of 12a-e and 13a-e. To a solution of 11 in CH 2 Cl 2 was added EDCI (1.1 eq), DMAP (0.5 eq) and isovaleric acid (1.0 eq) at 0 °C. The reaction mixture was stirred at ambient temperature for 1 h. After the completion of the reaction, saturated aq. NaHCO 3 was added for quenching. The mixture was extracted with EtOAc. A combined organic layer was washed with brine, dried over MgSO 4 and concentrated in vacuo. The residue was purified by column chromatography (CH 2 Cl 2 /MeOH) to afford 12 and 13.
